Smoking Cessation
Conditions
Brief summary
There are currently over 11 million cancer survivors in the U.S. and survival rates are increasing. Unfortunately, 10-30% of cancer patients are current smokers at the time of diagnosis, and many of these patients have elevated socioeconomic, medical, and psychosocial vulnerabilities. Documented risks associated with continued smoking following cancer diagnosis include decreased survival time; increased complications from surgery, radiation, and chemotherapy; and increased risk of second primary tumors. U.S. Department of Health & Human Services Public Health Service evidence-based tobacco treatment guidelines exist but have not been integrated into the cancer setting. This is a tremendous missed opportunity to address a modifiable risk factor. In recognition of this treatment gap, the National Cancer Institute (NCI) sponsored a conference in 2009 to address how to increase the readiness and capacity for delivery of tobacco treatment in Cancer Centers. The American Society of Clinical Oncology (ASCO) recommends identification, advice, and counseling of all smokers by their second oncology visit as a core quality indicator; however, currently only half of patients report being asked about tobacco use. Specific Aim: To conduct a randomized controlled comparative effectiveness trial of two strategies to promote smoking cessation in suspected or newly diagnosed cancer patients. Study Design: A multi-site randomized controlled comparative effectiveness trial will enroll 295 current smokers with suspected or newly diagnosed melanoma, lymphoma, thoracic, breast, genitourinary, gastrointestinal, head and neck, or gynecologic cancer. Participants will be randomly assigned to receive Intensive Counseling (IC) or Standard Care (SC). Both groups will receive an initial motivational counseling session and 3 weekly follow-up counseling sessions with a tobacco treatment counselor, conducted in-person or by telephone. The IC arm has the option to also receive: * Smoking Cessation Medication: Up to a 12-week supply of FDA approved smoking cessation medication (Varenicline, bupropion, or combination NRT) at no cost to the participant. * Extended Counseling: An additional 4 biweekly and 3 monthly proactive counseling sessions with a tobacco treatment counselor (total of 11 counseling contacts). All participants will complete 1 baseline and 2 follow-up surveys, at 3 and 6 months. Self-reported abstinence will be biochemically confirmed at 3 and 6 months.
Detailed description
Specific Aims Aim 1: To compare the effectiveness of two tobacco treatments that are integrated into cancer care in producing tobacco abstinence at 6 months. Aim 2: To explore: a) mechanisms through which treatment promotes abstinence; b) subpopulations in which abstinence is promoted; and c) which aspects of treatment promote abstinence. Aim 3: To compare the incremental cost effectiveness (cost per quit) of two tobacco treatments. Exploratory Aim: To identify the percentage and associated characteristics of smokers who 1) enroll in tobacco treatment and 2) adhere to tobacco treatment.
Interventions
BEHAVIORALStandard Care (SC)
1. Initial counseling session: The initial counseling session will last approximately 45 minutes and will be conducted in-person or by phone by a tobacco treatment counselor. The session will be structured in a 5 As format and utilize Motivational Interviewing (MI) techniques. 2. 3 Weekly Follow-up Counseling Sessions: SC Patients will be offered 3 weekly proactive follow-up sessions, concentrated on quitting and staying quit throughout cancer treatment. 3. Medication advice: The tobacco counselor will advise SC subjects to use smoking cessation medication to assist with their quit. Smoking cessation medication will not be provided by the study free of cost for SC subjects.
BEHAVIORALIntensive Counseling (IC)
The IC model includes all components of the SC as well as extended counseling support and up to 90 days of free FDA approved smoking cessation medication. 1. Extended counseling support: Participants in the IC group will be offered the same initial 4 counseling sessions as the SC group as well as 4 additional proactive biweekly sessions and 3 monthly booster sessions. 2. Smoking cessation medication: IC participants will be offered a 4-week supply of FDA-approved smoking cessation medication (varenicline, bupropion or nicotine replacement therapy) of their choice, with the option to renew the medication twice for up to 90 days of free medication. Participants are not required to take smoking cessation medication.
Sponsors
National Cancer Institute (NCI)
National Institutes of Health (NIH)
Massachusetts General Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Adult men and women may participate in this study if he/she meet the following requirements: 1. Current, new\* patient at one of our three participating study sites: Massachusetts General Hospital (MGH) Cancer Center, Memorial Sloan Kettering Cancer Center (MSKCC), or Dana-Farber Cancer Institute (DFCI); 2. Currently with suspected or newly diagnosed cancer (thoracic, breast, genitourinary, gastrointestinal, head and neck, gynecologic, lymphoma, melanoma); 3. Has smoked a cigarette, even a puff, in the past 30 days; 4. Is willing to consider trying to quit smoking using counseling and/or smoking cessation medication; 5. Is English or Spanish speaking (MGH); English speaking (MSK; DFCI); 6. Has regular telephone access. \[\*Patients will be considered new and eligible under the following conditions: 1. if they are attending approximately one of their first 4 visits or are within approximately 3 months of the initial visit date with their primary oncologist at the Massachusetts General Hospital (MGH) Cancer Center, Memorial Sloan Kettering Cancer Center (MSKCC), or Dana-Farber Cancer Institute (DFCI) for suspected or recently diagnosed cancer; 2. if they come to the MGH, MSKCC, or DFCI for a second opinion, the patient opts to receive their cancer treatment at any of these institutions; 3. if they have a past cancer diagnosis, they are currently faced with a local and distant recurrence of tumors; 4. if they have been treated previously for other types of cancer, they are currently faced with a new form of cancer.\]
Exclusion criteria
In an effort to be as inclusive as possible, a patient will be excluded only if he/she: 1. Is NOT currently receiving or has no intentions to receive care at one of three participating cancer treatment centers: Massachusetts General Hospital Cancer Center, Memorial Sloan Kettering Cancer Center, or Dana-Farber Cancer Institute (DFCI); 2. Is currently psychiatrically unstable or otherwise unable to provide informed consent as determined by study investigators or oncology clinician; 3. Is not English or Spanish speaking; 4. Is medically ineligible (as determined by their treating physician); 5. Has insufficient comprehension/literacy. ADDITIONAL INFORMATION: Participant inclusion/exclusion is not based on use of smoking cessation medication -- he/she may decide not to use any smoking cessation medication and still participate in the study. Patients deemed ineligible will be referred to the state quit line. Patients interested in participating in the study should contact the appropriate contact person, based on whether they are a current patient at the MGH, MSKCC, or DFCI.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Biochemically Verified 7-day Point Prevalence Tobacco Abstinence at 6 Months | 6 months | Number of participants with 7-day point-prevalence tobacco abstinence at 6-month follow-up, assessed by biochemically confirmed saliva cotinine (\<15 ng/ml76, 82) or \<10 ppm expired air carbon monoxide (CO) for participants concurrently using NRT |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Continuous Tobacco Abstinence | 3 months to 6 months | Number of Participants with Continuous tobacco abstinence (between quit and follow-up) at 3 & 6 months |
| Number of Participants With Sustained Tobacco Abstinence | 6 months | Number of Participants with Biochemically confirmed repeated point prevalence abstinence at 3 & 6 months |
| Number of Participants With Self-reported 7-day Point Prevalence. | 6 months | Number of Participants with Self-reported smoking abstinence of at least 7 days |
| The Number of IT Participants Who Used Smoking Cessation Pharmacotherapy | Treatment Initiation to 6 month follow-up | The number of IT participants who used 1) smoking cessation pharmacotherapy (Y/N dispensed) 2) smoking cessation counseling (Y/N), 3) 1-2 4-week refills, 4) took 1-3 monthly booster sessions. |
| Number of Participants With Biochemically Verified 7-day Point Prevalence Tobacco Abstinence at 3 Months | 3 months | Number of participants with7 -day point-prevalence tobacco abstinence at 3-month follow-up, assessed by biochemically confirmed saliva cotinine (\<15 ng/ml76, 82) or \<10 ppm expired air carbon monoxide (CO) for participants concurrently using NRT |
| The Number of IT Participants Who Took 1-2 4-week Refills | Treatment Initiation to 6 Month Follow-up | The number of intervention participants who took 1-2 4-week refills of smoking cessation medication |
| The Number of IT Participants Who Took 1-3 Monthly Booster Sessions | Treatment Initiation to 6 Month Follow-up | The number of IT participants who took 1-3 monthly booster sessions of smoking cessation counseling |
| Cost-effectiveness | 6 months | The cost of the standard of care treatment and the cost of the intensive treatment. |
| The Number of IT Participants Who Used Smoking Cessation Counseling | Treatment Initiation to 6 Month Follow-up | The number of intervention participants who used smoking cessation counseling during the study (Y/N) |
Countries
United States
Participant flow
Recruitment details
Between 11/25/2013 and 7/1/2017 4709 patients were screened for eligibility. 2659 were eligible based on screen criteria; 1808 did not complete the screen. Of the 851 who were approached to complete the screen, 405 were ineligible, 303 enrolled and were randomized, and 143 refused (84 refused consent and 59 did not complete the baseline survey)
Pre-assignment details
Of the 446 eligible for the study, 303 were randomized, 84 were eligible but refused consent (top 3 reasons: too upset, did not need help, had no time) and 59 were eligible but were not randomized because they did not complete a baseline survey.
Participants by arm
| Arm | Count |
|---|---|
| Standard Treatment (ST) Participants randomized to standard treatment will have the option to receive 4 behavioral counseling sessions with a tobacco treatment counselor and medication advice.
Standard Treatment (ST): (1) Initial counseling session: The initial counseling session will last approximately 45 minutes and will be conducted in-person or by phone by a tobacco treatment counselor. The session will be structured in a 5 As format and utilize Motivational Interviewing (MI) techniques.
(2) 3 Weekly Follow-up Counseling Sessions: ST Patients will be offered 3 weekly proactive follow-up sessions, concentrated on quitting and staying quit throughout cancer treatment.
(3) Medication advice: The tobacco counselor will advise SC subjects to use smoking cessation medication to assist with their quit. Smoking cessation medication will not be provided by the study free of cost for SC subjects. | 150 |
| Intensive Treatment (IT) Participants randomized to intensive treatment (IT) will receive the same 4 initial behavioral counseling sessions with a tobacco treatment counselor as participants in the SC arm. IC participants have the option to also receive:
* Extended Counseling: An additional 4 biweekly and 3 monthly proactive counseling sessions with a tobacco treatment counselor (total of 11 counseling contacts).
* Smoking Cessation Medication: Up to a 12-week supply of FDA approved smoking cessation medication \[varenicline, bupropion, or combination NRT (patch + lozenge)\] at no cost to the participant.
Intensive Counseling: The IT model includes all components of the ST as well as extended counseling support and up to 90 days of free FDA approved smoking cessation medication. | 153 |
| Total | 303 |
Baseline characteristics
| Characteristic | Standard Treatment (ST) | Total | Intensive Treatment (IT) |
|---|---|---|---|
| Age, Continuous | 58 years STANDARD_DEVIATION 9.5 | 58 years STANDARD_DEVIATION 9.7 | 58 years STANDARD_DEVIATION 9.9 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 4 Participants | 11 Participants | 7 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 146 Participants | 292 Participants | 146 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 3 Participants | 2 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 2 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 17 Participants | 31 Participants | 14 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 2 Participants | 2 Participants |
| Race (NIH/OMB) White | 131 Participants | 265 Participants | 134 Participants |
| Region of Enrollment United States | 150 participants | 303 participants | 153 participants |
| Sex: Female, Male Female | 83 Participants | 170 Participants | 87 Participants |
| Sex: Female, Male Male | 67 Participants | 133 Participants | 66 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 9 / 150 | 4 / 153 |
| other Total, other adverse events | 17 / 150 | 41 / 153 |
| serious Total, serious adverse events | 0 / 150 | 0 / 153 |
Outcome results
Primary
Number of Participants With Biochemically Verified 7-day Point Prevalence Tobacco Abstinence at 6 Months
Number of participants with 7-day point-prevalence tobacco abstinence at 6-month follow-up, assessed by biochemically confirmed saliva cotinine (\<15 ng/ml76, 82) or \<10 ppm expired air carbon monoxide (CO) for participants concurrently using NRT
Time frame: 6 months
Population: Twenty participants were too ill or deceased to complete follow-up assessment. Given the study participant population of cancer patients, our trial was powered accounting for cancer deaths and reporting participants who were alive at follow-up assessment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Standard Treatment (ST) | Number of Participants With Biochemically Verified 7-day Point Prevalence Tobacco Abstinence at 6 Months | 29 Participants |
| Intensive Treatment (IT) | Number of Participants With Biochemically Verified 7-day Point Prevalence Tobacco Abstinence at 6 Months | 51 Participants |
Secondary
Cost-effectiveness
The cost of the standard of care treatment and the cost of the intensive treatment.
Time frame: 6 months
Population: Cost per quit (in dollars) are shown below.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Standard Treatment (ST) | Cost-effectiveness | 638 dollars |
| Intensive Treatment (IT) | Cost-effectiveness | 1144 dollars |
Secondary
Number of Participants With Biochemically Verified 7-day Point Prevalence Tobacco Abstinence at 3 Months
Number of participants with7 -day point-prevalence tobacco abstinence at 3-month follow-up, assessed by biochemically confirmed saliva cotinine (\<15 ng/ml76, 82) or \<10 ppm expired air carbon monoxide (CO) for participants concurrently using NRT
Time frame: 3 months
Population: Twenty participants were too ill or deceased to complete follow-up assessment. Given the study participant population of cancer patients, our trial was powered accounting for cancer deaths and reporting participants who were alive at follow-up assessment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Standard Treatment (ST) | Number of Participants With Biochemically Verified 7-day Point Prevalence Tobacco Abstinence at 3 Months | 28 Participants |
| Intensive Treatment (IT) | Number of Participants With Biochemically Verified 7-day Point Prevalence Tobacco Abstinence at 3 Months | 46 Participants |
Secondary
Number of Participants With Continuous Tobacco Abstinence
Number of Participants with Continuous tobacco abstinence (between quit and follow-up) at 3 & 6 months
Time frame: 3 months to 6 months
Population: Twenty participants were too ill or deceased to complete follow-up assessment. Given the study participant population of cancer patients, our trial was powered accounting for cancer deaths and reporting participants who were alive at follow-up assessment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Standard Treatment (ST) | Number of Participants With Continuous Tobacco Abstinence | 26 Participants |
| Intensive Treatment (IT) | Number of Participants With Continuous Tobacco Abstinence | 43 Participants |
Secondary
Number of Participants With Self-reported 7-day Point Prevalence.
Number of Participants with Self-reported smoking abstinence of at least 7 days
Time frame: 6 months
Population: Twenty participants were too ill or deceased to complete follow-up assessment. Given the study participant population of cancer patients, our trial was powered accounting for cancer deaths and reporting participants who were alive at follow-up assessment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Standard Treatment (ST) | Number of Participants With Self-reported 7-day Point Prevalence. | 42 Participants |
| Intensive Treatment (IT) | Number of Participants With Self-reported 7-day Point Prevalence. | 54 Participants |
Secondary
Number of Participants With Sustained Tobacco Abstinence
Number of Participants with Biochemically confirmed repeated point prevalence abstinence at 3 & 6 months
Time frame: 6 months
Population: Twenty participants were too ill or deceased to complete follow-up assessment. Given the study participant population of cancer patients, our trial was powered accounting for cancer deaths and reporting participants who were alive at follow-up assessment.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Standard Treatment (ST) | Number of Participants With Sustained Tobacco Abstinence | 17 Participants |
| Intensive Treatment (IT) | Number of Participants With Sustained Tobacco Abstinence | 35 Participants |
Secondary
The Number of IT Participants Who Took 1-2 4-week Refills
The number of intervention participants who took 1-2 4-week refills of smoking cessation medication
Time frame: Treatment Initiation to 6 Month Follow-up
Population: Only assessed intensive treatment arm
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intensive Treatment (IT) | The Number of IT Participants Who Took 1-2 4-week Refills | 87 Participants |
Secondary
The Number of IT Participants Who Took 1-3 Monthly Booster Sessions
The number of IT participants who took 1-3 monthly booster sessions of smoking cessation counseling
Time frame: Treatment Initiation to 6 Month Follow-up
Population: Only assessed intensive treatment arm
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intensive Treatment (IT) | The Number of IT Participants Who Took 1-3 Monthly Booster Sessions | 99 Participants |
Secondary
The Number of IT Participants Who Used Smoking Cessation Counseling
The number of intervention participants who used smoking cessation counseling during the study (Y/N)
Time frame: Treatment Initiation to 6 Month Follow-up
Population: Only assessed intensive treatment arm
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intensive Treatment (IT) | The Number of IT Participants Who Used Smoking Cessation Counseling | 153 Participants |
Secondary
The Number of IT Participants Who Used Smoking Cessation Pharmacotherapy
The number of IT participants who used 1) smoking cessation pharmacotherapy (Y/N dispensed) 2) smoking cessation counseling (Y/N), 3) 1-2 4-week refills, 4) took 1-3 monthly booster sessions.
Time frame: Treatment Initiation to 6 month follow-up
Population: Only assessed intensive treatment arm.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intensive Treatment (IT) | The Number of IT Participants Who Used Smoking Cessation Pharmacotherapy | 122 Participants |